Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9Y2Z9

UPID:
COQ6_HUMAN

ALTERNATIVE NAMES:
Coenzyme Q10 monooxygenase 6

ALTERNATIVE UPACC:
Q9Y2Z9; B7Z3K8; Q53GG6; Q86U30; Q96CA1; Q96CK2

BACKGROUND:
The enzyme Ubiquinone biosynthesis monooxygenase COQ6, located in mitochondria, is essential for coenzyme Q10 synthesis, facilitating the electron transport chain's function. It achieves this by hydroxylating 3-hexaprenyl-4-hydroxybenzoic acid, a precursor in the ubiquinone pathway.

THERAPEUTIC SIGNIFICANCE:
Primary Coenzyme Q10 deficiency, particularly type 6, is attributed to genetic variants affecting COQ6, manifesting in early-onset renal failure and hearing loss. Targeting Ubiquinone biosynthesis monooxygenase COQ6's pathway offers a promising avenue for therapeutic intervention in such genetic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.